Alphagan

Known as: Alphagan® 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2017
012319992017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
PURPOSE To determine the proinflammatory cytokine profile of aqueous humor from glaucomatous eyes. METHODS Aqueous humor… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2005
2005
Aims Since its introduction in 1996, brimonidine tartrate 0.2% ophthalmic solution (Alphagan, Allergan) twice daily has become… (More)
  • table 1
  • table 2
  • table 3
  • table 5
  • figure 1
Is this relevant?
2003
2003
The tolerability of brimonidine tartrate 0.15%--referred to as bromonidine-Purite 0.15% in this study--was compared with… (More)
Is this relevant?
2002
2002
PURPOSE To compare the efficacy and safety of brimonidine-Purite (Alphagan; Allergan, Irvine, CA) 0.15% and 0.2% three times… (More)
Is this relevant?
2002
2002
Purite (stabilized oxychloro complex) and benzalkonium chloride (BAK) are preservatives. We investigated formulation effects on… (More)
Is this relevant?
2001
2001
OBJECTIVE To determine the vitreous concentration of brimonidine after topical administration of Alphagan. DESIGN Prospective… (More)
Is this relevant?
2000
2000
PURPOSE The main purpose of our study was to assess the systemic safety of brimonidine tartrate 0.2%, an alpha 2 highly selective… (More)
Is this relevant?
2000
2000
PURPOSE To report anterior uveitis as a late side-effect of topical brimonidine tartrate 0.2% (Alphagan; Allergan Inc., Irvine… (More)
Is this relevant?
1999
1999
PURPOSE To determine the calculated daily patient cost (cost minimization) of medical glaucoma therapy. METHODS The actual… (More)
Is this relevant?